TNFRSF4 and central nervous system cancer: The so far conducted pre-clinical studies have evaluated agonistic OX40-antibodies, which were found to promote tumor regression in melanoma-, colon carcinoma-, and glioma-models, by reinforcing the immune response against the malignant cells18–20.